CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its ...

CVS Health posted impressive Q1 2025 results with jumps in revenue, net income, and sales, yet it still decided to rain on ...

Strong results in CVS Health’s healthcare services division in the first quarter of 2025 drove, in part, robust sales and profits at the retail pharmacy chain.

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

A federal jury in New York has returned “one of the largest damages verdicts rendered by a jury in a False Claims Act case” — almost $136 million, with an owed amount that is expected to grow to more ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

An examination of recent litigation under the Employee Retirement Income Security Act of 1974 (ERISA) challenging allegedly ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...